NL-OMON40942已完成不适用
Controlled Human Malaria Infection after bites from mosquitoes infected with NF135.C10 or NF166.C8 Plasmodium falciparum parasites - BMGF2a
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Subject is aged >= 18 and <= 35 years and in good health.
- •2. Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
- •3. Subject is able to communicate well with the investigator, is available to attend all study visits and lives in proximity to the trial centre (<10 km) or (if >10km) is willing to stay in a hotel close to the trial centre during part of the study (day 5 post-infection until three days post-treatment). Furthermore the subject will remain within the Netherlands during the study period and is reachable (24/7) by mobile telephone throughout the entire study period.
- •4. Subject agrees to inform his/her general practitioner about participation in the study and to sign a request to release by the GP any relevant medical information concerning possible contra-indications for participation in the study.
- •5. Subject agrees to refrain from blood donation to Sanquin or for other purposes throughout the study period and for a defined period thereafter according to current Sanquin guidelines.
- •6. For female subjects: subject agrees to use adequate contraception and not to breastfeed for the duration of study.
- •7. Subject has signed informed consent.
排除标准
- •1. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immunodeficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following:
- •1.1 Body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening
- •1.2 A heightened risk of cardiovascular disease, defined as: an estimated ten year risk of fatal cardiovascular disease of >=5% at screening, as determined by the Systematic Coronary Risk Evaluation (SCORE); history, or evidence at screening, of clinically significant arrhythmia*s, prolonged QT-interval or other clinically relevant ECG abnormalities; or a positive family history of cardiac events in 1st or 2nd degree relatives <50 years old.
- •1.3 Functional asplenia, sickle cell trait/disease, thalassaemia trait/disease or G6PD deficiency.
- •1.4 History of epilepsy in the period of five years prior to study onset, even if no longer on medication.
- •1.5 Positive HIV, HBV or HCV screening tests.
- •1.6 Chronic use of i) immunosuppressive drugs, ii) antibiotics, iii) or other immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period.
- •1.7 History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years
- •1.8 Any history of treatment for severe psychiatric disease by a psychiatrist in the past year.
- •1.9 History of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset, or positive urine toxicology test for cocaine or amphetamines at screening or prior to infection.
- •2. For female subjects: positive urine pregnancy test at screening or prior to infection.
- •3. Any history of malaria, positive serology for P. falciparum, or previous participation in any malaria (vaccine) study.
- •4. Known hypersensitivity to or contra-indications (including co-medication) for use of atovaquone-proguanil (Malarone) or artemether-lumefantrine (Riamet), or history of severe (allergic) reactions to mosquito bites.
- •5. Receipt of any vaccinations in the 3 months prior to the start of the study or plans to receive any vaccinations during the study period or up to 8 weeks thereafter.
- •6. Participation in any other clinical study in the 30 days prior to the start of the study or during the study period.
- •7. Being an employee or student of the department of Medical Microbiology of the Radboudumc, the department of Internal Medicine or Laboratory of the Havenziekenhuis or the department of Medical Microbiology & Infectious Diseases of the Erasmus MC.
- •8. Any other condition or situation that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
研究者
相似试验
进行中（未招募）
1 期
Controlled human malaria infection after immunization with frozen Plasmodium falciparum parasites under chloroquine prophylaxisEUCTR2012-000322-21-NLSanaria Inc.
已完成
不适用
Experimental human malaria infection after immunization with Plasmodium falciparum sporozoites under chloroquine prophylaxis.Plasmodium falciparum10037072MalariaNL-OMON36473niversitair Medisch Centrum Sint Radboud25
已完成
不适用
Experimental human malaria infection by intradermal injection of Plasmodium falciparum sporozoites (PfSPZ Challenge)10037072MalariaNL-OMON35056Sanaria Inc., Stephen L. Hoffman, M.D.18
Unknown
2 期
Controlled Human Malaria Infection evaluation of Plasmodium falciparum malaria vaccine ProC6C-AlOH/Matrix-Mtm in healthy Malian adultsMalariaPACTR202404598604620niversity of Sciences Techniques and Technologies of Bamako34
尚未招募
1 期
In-vivo Transmission model in semi-immune adultsMalariaPACTR202312585218142Ifakara Health Institute24